GlassScriptPhysician profile
Amy S Valet
NPI 1891999389
$6,276.05
in general payments reported to CMS, 2019-2025
35 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $328 · 2021: $707 · 2022: $1,102 · 2023: $1,289 · 2024: $1,108 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.14 |
| Education | $128.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $978.76 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $669.68 | 2021-2025 | Ilumya |
| Pfizer INC. | $666.27 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $563.21 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $505.27 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $442.90 | 2024-2025 | Tremfya |
| Incyte Corporation | $293.03 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $283.19 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $266.62 | 2021-2025 | Nemluvio, Oracea, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $222.91 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $219.34 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $120.35 | 2019-2021 | |
| Dermavant Sciences, INC. | $117.75 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $107.46 | 2024-2025 | |
| Glaxosmithkline, LLC. | $103.08 | 2020-2023 | Trelegy Ellipta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $94.51 | 2019-2024 | Haegarda |
| Ucb, INC. | $90.61 | 2023-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $64.60 | 2019-2021 | |
| Octapharma USA, INC. | $59.87 | 2021 | |
| Genentech USA, INC. | $59.27 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $51.23 | 2021-2023 | Hyqvia, Cuvitru |
| Grifols USA, LLC | $40.38 | 2022-2024 | Xembify |
| Journey Medical Corporation | $38.94 | 2022-2025 | |
| Pharming Healthcare, INC. | $23.12 | 2022 | |
| Almirall LLC | $21.62 | 2025 | Seysara |
| Botanix Sb INC | $20.51 | 2025 | Sofdra |
| Organon LLC | $20.33 | 2025 | Vtama |
| Celgene Corporation | $19.68 | 2019 | |
| Shire North American Group INC | $19.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.01 | 2023 | Cyltezo |
| Leo Pharma INC. | $17.75 | 2024 | Adbry |
| Paratek Pharmaceuticals, INC. | $15.76 | 2025 | Nuzyra |
| Arcutis Biotherapeutics, INC. | $15.53 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Valet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.